Alibaba Was Not the Only IPO This Week

Photo of Paul Ausick
By Paul Ausick Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

initial public offering
Thinkstock
What may be the world’s largest-ever initial public offering (IPO) is about to begin trading Friday, and the anticipation might suck all the air out of the IPO room. When Alibaba Group Holding Ltd. (NYSE: BABA) begins trading this morning even the vote rejecting independence in Scotland will have to fight for headline space.

Speaking of overlooked, there were six other IPOs scheduled to begin trading this week. Wisely none chose to go out on the same day as Alibaba.

The IPO week started on Wednesday with Civitas Solutions Inc. (NYSE: CIVI), which claims to be the country’s leading provider of in-home and community-based health services. Shares priced at $17, well below the expected range of $20 to $23, and dipped to $16.16 on its opening day. Shares closed at $16.61 on Thursday.

A clinical-stage biopharmaceutical company developing treatments for prostate cancer and other hormonally driven diseases, Tokai Pharmaceuticals Inc. (NASDAQ: TKAI) also began trading on Wednesday. The company upsized its offering from 5.4 million shares to 6.5 million and priced the shares at $15, the top of the expected range. The stock jumped above $28 before closing its first trading day at $23.76. Shares closed Thursday at $19.77 and traded down another 3.6% in Friday’s premarket session to $19.05.

Foamix Ltd. (NASDAQ: FOMX) is an Israel-based clinical-stage pharmaceutical firm developing a foam treatment for acne, impetigo and other skin conditions. The company upsized the number of shares on offer from 5.9 million to 6.7 million, but priced the shares at $6, way below the expected range of $10 to $12. After popping to $11 shortly after trading began on Thursday, shares closed at $6.22, and they traded at $6.14 in Friday’s premarket.

Dutch biopharma firm ProQR Therapeutics B.V. (NASDAQ: PRQR) is developing RNA-based therapeutics for treating severe genetic disorders. ProQR also upsized the number of shares it offered on Thursday, from 6.3 million to 7.5 million, and priced the shares at $13, the top end of its expected range. Shares peaked at $21.87 before closing at $14.73. The stock was trading down about 2.2% in Friday’s premarket session.

Two other IPOs scheduled for this week have been delayed: Viking Therapeutics and rEVO Biologics are both currently listed as day-to-day regarding pricing and trading dates.

ALSO READ: Six Stocks Portfolio Managers Are Selling to Fund New Alibaba Stakes

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618